Impact of UFT on Tumoral TS and DPD Levels in Colorectal Cancer
ByGerard Bastian, PhD,Jean-franÇois Seitz, MD,Vincent Moutardier, MD,Jean Robert Delperro, MD,Pierre Fargeot, MD,Jean Fraisse, MD,Patricia Formento, PhD,Michel Chazard, MD,Nicole Renée, PhD,Gerard Milano, PhD
Published: | Updated:
This was an open lable, pilot translational clinical pharmacology study of a brief (7 day) course of UFT, 300 mg/m²/day, in combination with leucovorin, 90 mg/day, in six patients with newly diagnosed advanced colorectal cancer.